ArticleBMC cancer2023
Impact of sex on treatment-related adverse effects and prognosis in nasopharyngeal carcinoma.
Article in BMC cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.
- Chronotherapy in head and neck cancer: A systematic review and meta-analysis.International journal of cancer · 2025Pooled it
- Gender role in radiotherapy: psychosocial differences between males and females during cancer care : Single-centre report on adult and paediatric oncological patients.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2026Article
- Morphological analysis of anatomical structure of nasopharynx in cone-beam computed tomography in Korean population.Imaging science in dentistry · 2026Article
- Dynamic disease progression in non-metastatic nasopharyngeal carcinoma post-radical radiotherapy: a Markov model-based analysis in a Chinese cohort.Therapeutic advances in medical oncology · 2026Article
- A Clinical-Radiomics Nomogram Based on Pretreatment Magnetic Resonance Imaging Predicting Tumor Residual at the End of Radiotherapy in Patients With Nasopharyngeal Carcinoma.International journal of biomedical imaging · 2026Article
- Global burden and trends of common head and neck cancers between 1990 and 2021: findings from the Global Burden of Disease Study 2021.BMC oral health · 2025Article
- Patient Characteristics and Treatment Outcomes of Nasopharyngeal Carcinoma in Nonendemic Regions.JAMA network open · 2025Article
- Impact of magnetic resonance imaging-defined sarcopenia on prognosis in patients with locally advanced nasopharyngeal carcinoma.Discover oncology · 2025Article
- Article
- GNA14 may be a potential prognostic biomarker in nasopharyngeal carcinoma.Frontiers in oncology · 2024Article
- Gender-Specific Survival of Nasopharyngeal Carcinoma in Endemic and Non-Endemic Areas Based on the US SEER Database and a Chinese Single-Institutional Registry.Clinical epidemiology · 2024Article
- Burden and Trends of Nasopharyngeal Cancer Among Younger People in the Western Pacific Region, 1990 to 2021: Findings from the 2021 Global Burden of Disease Study.Journal of otolaryngology - head & neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-facialeArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundIn nasopharyngeal cancer (NPC), women have a lower incidence and mortality rate than men. Whether sex influences the prognosis of NPC patients remains debatable. We retrospectively examined the influence of sex on treatment-related side effects and prognosis in NPC.
methodsClinical data of 1,462 patients with NPC treated at the Southern Hospital of Southern Medical University from January 2004 to December 2015 were retrospectively examined. Statistical analysis was performed to assess differences in overall survival (OS), distant metastasis-free survival (DMFS), local recurrence-free survival(LRFS), and progression-free survival(PFS), as well as treatment-related adverse effects, including myelosuppression, gastrointestinal responses, and radiation pharyngitis and dermatitis, between men and women.
resultsWomen had better 5-year OS (81.5% vs. 87.1%, P = 0.032) and DMFS (76.2% vs. 83.9%, P = 0.004) than men. Analysis by age showed that the prognoses of premenopausal and menopausal women were better than those of men, whereas prognoses of postmenopausal women and men were not significantly different. Additionally, women had a better prognosis when stratified by treatment regimen. Furthermore, chemotherapy-related adverse effects were more severe in women than in men; however, the incidences of radiation laryngitis and dermatitis were not significantly different between the sexes. Logistic regression analysis revealed that the female sex was an independent risk factor for severe myelosuppression and gastrointestinal reactions.
conclusionsChemotherapy-related side effects are more severe but the overall prognosis is better in women with NPC than in men with NPC. Patients may benefit from a personalized treatment approach for NPC.
trial registrationThis study was approved by the Medical Ethics Committee of Nanfang Hospital of the Southern Medical University (NFEC-201,710-K3).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.